Core Message {#FPar1}
============

There is a need for novel vaccine technologies where existing viral vaccine types (viruses, killed or inactivated viruses, and conjugate or subunits) are unsuitable against many viruses. Hence, short peptide (10--20 residues) vaccine candidates are considered promising solutions in recent years. These function on the principle of short epitopes developed through the binding of CD8+/CD4+-specific HLA alleles (12542 known so far). Thus, the specific binding of short peptide antigens to HLA alleles is rate limiting with high sensitivity in producing T-cell-mediated immune responses. Identification of HLA allele-specific antigen peptide binding is mathematically combinatorial and thus complex. Therefore, prediction of HLA allele-specific peptide binding is critical. Recent advancement in immune-informatics technologies with the aid of known X-ray-determined HLA-peptide structure data provides solutions for the accurate identification of short peptides as vaccine candidates for further consideration. Thus, we document the possibilities and challenges in the prediction, large-scale screening, development, and validation of short peptide vaccine candidates in this chapter.

Introduction {#Sec1}
============

The types of approved viral vaccines include live attenuated viruses, killed/inactivated viruses, and conjugate/subunits. However, these types of vaccine technologies may prove unsuitable against some viruses. In some cases, there is interest in the development of short peptide vaccines to fill the gaps. For example, the use of live attenuated HIV-1/AIDS vaccines is not as yet approved due to safety concerns \[[@CR1]\]. There are several subunit vaccines under consideration and evaluation. However, one of these, the NIAID and Merck Co.-sponsored 2004 STEP (HVTN 502 or Merck V520-023) trial using three recombinant adenovirus-5 (rAD5) vectors containing HIV-1 genes Ad5-gag, Ad5-pol, and Ad5-Nef, did not show promising results \[[@CR2]\]. This has led to the development of a multifaceted strategy for HIV-1/AIDS vaccine development. However, encouraging results were observed with four priming injections of a recombinant canary pox vector (ALVAC-HIV) and two booster injections of gp120 subunit (AIDSVAX-B/E) in a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial (NCT00223080) in Thailand \[[@CR3]\]. The main concern following this study was that this vaccine did not affect the degree of viremia or the CD4 T-cell count in patients who later seroconverted. Further studies indicated that the challenges with the development of an HIV-1/AIDS vaccine are viral diversity and host-virus molecular mimicry \[[@CR4]--[@CR6]\]. Nonetheless, there is considerable amount of interest to develop gp160 (gp120-gp41 complex) TRIMER envelope (ENV) protein as a potential vaccine candidate \[[@CR4]\].

The production of an HIV-1 ENV spike protein trimer complex is nontrivial due to protein size, protein type, sequence composition, and residue charge polarity. Therefore, the need for the consideration of alternative approaches for vaccine development such as T-cell-based HLA-specific short peptide vaccines is promising \[[@CR6], [@CR7]\]. The LANL HIV molecular immunology database provides comprehensive information on all known T-cell epitopes in the literature \[[@CR8]\]. Thus, these resources in combination with other predictive advancements described in this chapter are collectively useful for the design, development, evaluation, and validation of short peptide vaccine candidates.

Methodology {#Sec2}
===========

Structural Data {#Sec3}
---------------

A structural dataset of complexes for class I HLA-peptide (Table [1.1](#Tab1){ref-type="table"}) and class II HLA-peptide (Table [1.2](#Tab2){ref-type="table"}) is created from the protein databank (PDB) \[[@CR9]\]. The characteristic features of the datasets are presented in Tables [1.1](#Tab1){ref-type="table"} and [1.2](#Tab2){ref-type="table"}.Table 1.1Dataset of class 1 HLA-peptide structures downloaded from PDBSCodeAllelePeptide sequenceLSourceRÅYearGroupCountryState11 W72A\*0101EADPTGHSY9Melanoma related2.152004Ziegler AGermanyBerlin23BO8A\*0101EADPTGHSY9Melanoma related1.82008Ziegler UBGermanyBerlin33UTSA\*0201ALWGPDPAAA10Insulin2.712012Andrew SKUKCardiff43UTTA\*0201ALWGPDPAAA10Insulin2.62012Sewell AKUKCardiff51I4FA\*0201GVYDGREHTV10Melanoma related1.42001Mabbutt BCAustraliaSydney61JHTA\*0201ALGIGILTV9Mart-12.152001Wiley DCUSACambridge71B0GA\*0201ALWGFFPVL9Human-peptide2.61998Collins EJUSANorth Carolina81I7UA\*0201ALWGFVPVL9Synthetic1.82001Collins EJUSANorth Carolina91I7TA\*0201ALWGVFPVL9Synthetic2.82001Collins EJUSANorth Carolina101I7RA\*0201FAPGFFPYL9Synthetic2.22001Collins EJUSANorth Carolina111I1FA\*0201FLKEPVHGV9HIV RT2.82000Collins EJUSANorth Carolina121HHIA\*0201GILGFVFTL9Synthetic2.51993Wiley DCUSAMassachusetts131AKJA\*0201ILKEPVHGV9HIV-1 RT2.651997Jakobsen BKUKOxford141HHJA\*0201ILKEPVHGV9Synthetic2.51993Wiley DCUSAMassachusetts151QRNA\*0201LLFGYAVYV9Tax peptide P6A2.81999Wiley DCUSAMassachusetts161QSEA\*0201LLFGYPRYV9Tax peptide V7R2.81999Wiley DCUSAMassachusetts171QSFA\*0201LLFGYPVAV9Tax peptide Y8A2.81999Wiley DCUSAMassachusetts181AO7A\*0201LLFGYPVYV9HTLV-1 Tax2.61997Wiley DCUSAMassachusetts191BD2A\*0201LLFGYPVYV9HTLV-1 Tax2.51998Wiley DCUSAMassachusetts201DUZA\*0201LLFGYPVYV9HTLV-1 Tax1.82000Wiley DCUSAMassachusetts211HHKA\*0201LLFGYPVYV9Synthetic2.51993Wiley DCUSAMassachusetts221IM3A\*0201LLFGYPVYV9HTLV-1 Tax2.22001Wiley DCUSABoston231HHGA\*0201TLTSCNTSV9HIV-1 gp1202.61993Wiley DCUSAMassachusetts241I1YA\*0201YLKEPVHGV9HIV-1 RT2.22000Collins EJUSANorth Carolina253FQNA\*0201YLDSGIHSGA10Beta-catenin1.652009Purcell AWAustraliaVictoria263FQRA\*0201YLDGIHSGA10Beta-catenin1.72009Purcell AWAustraliaVictoria273FQTA\*0201GLLGSPVRA9Tyrosine-phosphatase1.82009Purcell AWAustraliaVictoria283FQUA\*0201GLLGSPVRA9Tyrosine-phosphatase1.82009Purcell AWAustraliaVictoria293FQWA\*0201RVASPTSGV9Insulin receptor1.932009Purcell AWAustraliaVictoria303FQXA\*0201RVASPTSGV9Insulin receptor1.72009Purcell AWAustraliaVictoria311QQDA\*0201QYDDAVYKL9HLA-CW42.71999Wiley DCUSAMassachusetts321P7QA\*0201ILKEPVHGV9POL polyprotein3.42003Bjorkman PJUSACalifornia332HN7A\*1101AIMPARFYPK9DNA polymerase1.62006Gajhede MDenmark.Copenhagen341X7QA\*1101KTFPPTEPK9SARS nucleocapsid1.452005Gajhede MDenmark.Copenhagen353BVNB\*1402RRRWRRLTV9Latent membrane2.552009Ziegler AGermanyBerlin363BP4B\*2705IRAAPPPLF9Lysosomal1.852008Ziegler AGermanyBerlin371HSAB\*2705ARAAAAAAA9N/A2.11992Wiley DCUSAMassachusetts381JGEB\*2705GRFAAAIAK9Synthetic (M9)2.12002Ziegler UBGermanyBerlin391OF2B\*2709RRKWRRWHL9Intestinal2.22004Ziegler UBGermanyBerlin401JGDB\*2709RRLLRGHNQY10s10R1.92003Ziegler A.GermanyBerlin411K5NB\*2709GRFAAAIAK9Synthetic (M9)1.092002Ziegler UBGermanyBerlin423BP7B\*2709IRAAPPPLF9Lysosomal1.82008Ziegler A.GermanyBerlin431ZSDB\*3501EPLPQGQLTAY11BZLF11.72005McCluskey JAustraliaBrisbane441A9BB\*3501LPPLDITPY9EBNA-3C3.21998Saenger WGermanyBerlin451A9EB\*3501LPPLDITPY9EBV-Ebna3c2.51998Saenger WGermanyBerlin463LN4B\*4103AEMYGSVTEHPSPSPL16Ribonucleo protein1.32010Blasczyk RGermanyHannover473LN5B\*4104HEEAVSVDRVL11Thioadenosine1.92010Blasczyk RGermanyHannover483DX6B\*4402EENLLDFVRF10EBV decapeptide1.72009Rossjohn JAustraliaVictoria493DX7B\*4403EENLLDFVRF10EBV decapeptide1.62009Rossjohn JAustraliaVictoria501SYSB\*4403EEPTVIKKY9Sorting nexin 52.42004McCluskey JAustraliaVictoria513DXAB\*4405EENLLDFVRF10EBV decapeptide3.52009Rossjohn JAustraliaVictoria523DX8B\*4405EENLLDFVRF10EBV decapeptide2.12009Rossjohn JAustraliaVictoria531E27B\*5101LPPVVAKEI9HIV-1 Kml2.22000Jones EYUKOxford541A1MB\*5301TPYDINQML9HIV-2 gag2.31998Jones EYUKOxford551A1OB\*5301KPIVQYDNF9HIV-1 Nef2.31998Jones EYUKOxford563VRJB\*57:01LTTKLTNTN10Cytochrome c Oxidase1.92012McCluskey JAustraliaVictoria573UPRB\*57:01HSITYLLPV9Synthetic construct22012Peters BUSAGainesville583VRIB\*57:01RVAQLEQVYI10SNRPD31.62012McCluskey JAustraliaVictoria592RFXB\*5701LSSPVTKSF9Synthetic construct2.52008McCluskey JAustraliaVictoria603VH8B\*5701LSSPVTKSF9Ig kappa chain C region1.82011Rossjohn JAustraliaVictoria612DYPB27RIIPRHLQL9Histone H2A.x2.52006Maenaka KJapanFukuoka622D31B27RIIPRHLQL9Histone H2A.x3.22006Maenaka KJapanFukuoka631EFXCw\*0304GAVDPLLAL9Importin-232000Sun PDUSAMaryland641IM9Cw\*0401QYDDAVYKL9Synthetic2.82001Wiley DCUSACambridge653CDGGVMAPRTLFL9Synthetic construct3.12008Rossjohn JAustraliaVictoria663KYNGKGPPAALTL9Synthetic construct2.42010Clements CSAustraliaVictoria673KYOGKLPAQFYIL9Synthetic construct1.72010Clements CSAustraliaVictoriaS = Serial number; Code = PDB code; L = Length of peptide; R = Resolution Table 1.2Dataset of class 2 HLA-peptide structures downloaded from PDBSCodeAllelePeptide sequenceLSourceRÅYearGroupCountryState11UVQDC1EGRDSMNLPSTKVSWAAVGGGGSLVPRGSGGGG33Human Orexin1.82004Fugger LUKOxford21S9VDQ1LQPFPQPELPY11Synthetic2.22004Sollid LMUSAStanford32NNADQ8QQYPSGEGSFQPSQENPQ18Gluten2.12006Anderson RPAustraliaVictoria41JK8DQ8LVEALYLVCGERGG14Human insulin2.42001Wiley DCUSABoston54GG6DQ1QQYPSGEGSFQPSQENPQ18MM13.22012Rossjohn JAustraliaVictoria61KLGDR1GELIGILNAAKVPAD15Synthetic2.42001Mariuzza RAUSAMaryland71KLUDR1GELIGTLNAAKVPAD15Synthetic1.92001Mariuzza RAUSAMaryland81T5WDR1AAYSDQATPLLLSPR15Synthetic2.42004Stern LJUSAMassachusetts92IANDR1GELIGTLNAAKVPAD15Human2.82006Mariuzza RAUSAMaryland102FSEDR1AGFKGEQGPKGEPG14Collagen3.12006Park HWUSAMemphis111SJHDR1PEVIPMFSALSEG13HIV12.22004Stern LJUSACambridge122Q6WDR1AWRSDEALPLGS12Integrin2.22007Stern LJUSACambridge131ZGLDR2VHFFKNIVTPRTPGG15Myelin2.82005Mariuzza RAUSAMaryland141H15DR2GGVYHFVKKHVHES14EPV related3.12002Fugger LUKOxford151A6ADR3PVSKMRMATPLLMQA15Human CLIP2.71998Wiley DCUSAMassachusetts162SEBDR4AYMRADAAAGGA12Collagen2.51997Wiley DCUSAMassachusettsS = Serial number; Code = PDB code; L = Length of peptide; R = Resolution

Structural Superposition of HLA Molecules {#Sec4}
-----------------------------------------

The peptide-binding grooves of both class I HLA (Fig. [1.1a](#Fig1){ref-type="fig"}) and class II HLA (Fig. [1.1c](#Fig1){ref-type="fig"}) molecules were superimposed using the molecular overlay option in the Discovery Studio software from Accelrys^®^ \[[@CR10]\].Fig. 1.1The structural basis for short peptide vaccine design is illustrated. The allele-specific nomenclature defined, ethnicity profiled using known HLA sequences at the IMGT/HLA database \[[@CR11]\], and the striking backbone structural similarity of antigen peptides at the HLA binding groove is the bottleneck. This is generated with using a dataset (Tables [1.1](#Tab1){ref-type="table"} and [1.2](#Tab2){ref-type="table"}) of HLA-peptide complexes (67 class I and 16 class II) retrieved from protein databank (PDB) \[[@CR9]\] using with Discovery Studio^®^ (Accelrys Inc.) \[[@CR10]\]. (**a**) The peptide-binding groove (superimposed) in class I HLA is structurally similar among known alleles and complexes. (**b**) The peptide-binding groove (superimposed) in class II HLA is structurally similar among known alleles and complexes; (**c**) class I HLA-bound peptides overlay showing structural constraints (bend peptides) at the groove; (**d**) class II bound peptides overlay showing extended conformation at the groove. This clearly suggests that class I (panel **c**) and class II (panel **d**) bound peptides do not have identical binding patterns at the groove

Molecular Overlay of HLA-Bound Peptides {#Sec5}
---------------------------------------

HLA-bound peptides in the groove of both class I HLA (Fig. [1.1b](#Fig1){ref-type="fig"}) and class II HLA (Fig. [1.1d](#Fig1){ref-type="fig"}) molecules were overlaid using the molecular overlay option in the Discovery Studio software from Accelrys^®^ \[[@CR10]\].

Accessible Surface Area Calculations {#Sec6}
------------------------------------

Accessible surface area (ASA) was calculated using the WINDOWS software Surface Racer \[[@CR12]\] with Lee and Richard implementation \[[@CR13]\]. A probe radius of 1.4 Å was used for ASA calculation.

Relative Binding Measure {#Sec7}
------------------------

Relative binding measure (RBM) is defined as the percentage ASA Å^2^ of residues in the peptide at the corresponding positions buried as a result of binding with the HLA groove. This is the percentage change in ASA (ΔASA) of the position-specific peptide residues upon complex formation with the HLA groove (Fig. [1.2](#Fig2){ref-type="fig"}).Fig. 1.2The peptide binding pattern at the groove is illustrated as function of residue position for class I and class II alleles using a dataset (Tables [1.1](#Tab1){ref-type="table"} and [1.2](#Tab2){ref-type="table"}) of HLA-peptide complexes (67 class I and 16 class II) retrieved from protein databank (PDB). This dataset is represented by several class I and class II alleles (see Tables [1.1](#Tab1){ref-type="table"} and [1.2](#Tab2){ref-type="table"}). The peptide lengthwise distribution of the binding pattern is shown as relative binding measure using change in solvent-accessible surface area upon complex formation with the HLA groove

Results and Discussion {#Sec8}
======================

HLA-Peptide Binding Prediction for T-Cell Epitope Design {#Sec9}
--------------------------------------------------------

The rate-limiting step in T-cell epitope design is allele-specific HLA-peptide binding prediction. The number of known HLA alleles is over 12542 in number as of March 2015 at the IMGT/HLA database \[[@CR11]\]. Hence, a number of methods have been formulated so far and optimized for HLA-peptide binding prediction during the last two decades. Structural information on HLA-peptide complexes has increased our understanding of their binding patterns (Tables [1.1](#Tab1){ref-type="table"} and [1.2](#Tab2){ref-type="table"}). The HLA-binding groove is structurally similar among class I (Fig. [1.1a](#Fig1){ref-type="fig"}) and class II (Fig. [1.1b](#Fig1){ref-type="fig"}) alleles. The class I (Fig. [1.1c](#Fig1){ref-type="fig"}) and class II (Fig. [1.1d](#Fig1){ref-type="fig"}) bound peptides do not show an identical binding pattern at the groove. A detailed illustration of peptide binding patterns (Fig. [1.2](#Fig2){ref-type="fig"}) at the groove of class I and class II alleles provides valuable insights using mean and deviation profiles (Fig. [1.3](#Fig3){ref-type="fig"}).Fig. 1.3The mean peptide binding pattern with standard deviation (SD) at the groove is illustrated as function of residue position for class I and class II alleles using a dataset (Tables [1.1](#Tab1){ref-type="table"} and [1.2](#Tab2){ref-type="table"}) of HLA-peptide complexes (67 class I and 16 class II) retrieved from protein databank (PDB). This provides insight into the understanding of the nature of peptide binding at the groove towards the design of an effective T-cell epitope candidate

A comprehensive description of HLA-peptide binding prediction is documented \[[@CR14], [@CR15]\]. Lee and McConnell \[[@CR16]\] proposed a general model of invariant chain association with class II HLA using the side-chain packing technique on a known structural template complex with self-consistent ensemble optimization (SCEO) \[[@CR17], [@CR18]\] using the program CARA in the molecular visualization/modeling software LOOK (Molecular Application Group (1995), Palo Alto, CA) \[[@CR16], [@CR19]\]. This was an important development in the field and the approach was extended to a large dataset of known HLA-binding peptides. Kangueane et al. \[[@CR20]\] collected over 126 class I peptides with known IC~50~ values from literature with defined HLA allele specificity. These peptides were modeled using available templates for a large-scale assessment of peptide binding to defined HLA alleles. Thus, a structural framework was established for discriminating allele-specific binders from non-binders using rules derived from a dataset of HLA-peptide complexes. This procedure was promising.

An extended dataset of class 1 and class 2 complexes were manually created, curated, and analyzed for insights into HLA-peptide binding patterns at the groove \[[@CR21]\]. These studies lead to a detailed analysis of the HLA-peptide interface at the groove and the importance of peptide side chain and backbone atomic interactions were realized \[[@CR22]\]. Meanwhile, the amount of structural data on HLA-peptide complexes was increasing in size leading to the development of an online database \[[@CR23]\]. Thus, information gleaned from HLA-peptide structural complexes helped to identify common pockets among alleles in the binding groove and provided insights into functional overlap among them \[[@CR24]\]. The need for a simple, robust, generic HLA-peptide binding prediction was evident. Therefore, a model was formulated by defining virtual pockets at the peptide-binding groove using information gleaned from a structural dataset of HLA-peptide complexes \[[@CR25]\]. The model (average accuracy of 60 %) was superior because of its application to any given class I allele whose sequence is clearly defined. The model (53 % accuracy) was then extended for class II prediction using a class II-specific HLA-peptide structural dataset \[[@CR26]\].

The techniques thus far established are highly promising towards short peptide vaccine design and development \[[@CR27], [@CR28]\]. Nonetheless, it was observed that alleles are covered within few HLA supertypes, where different members of a supertype bind similar peptides, yet exhibiting distinct repertoires \[[@CR29]\]. These principles led to the development of frameworks to group alleles into HLA supertypes \[[@CR30], [@CR31]\], understand their structural basis \[[@CR32]\], and cluster alleles based on electrostatic potential at the groove \[[@CR33]\]. These observations should aid in the design of peptide vaccine candidates for viruses including HIV/AIDS \[[@CR5], [@CR6]\]. Further, for example, the importance of protein modifications to enhance HIV-1 ENV trimer spike protein vaccine across multiple clades, blood, and brain is discussed \[[@CR4]\]. Currently available types of vaccine technology \[[@CR34], [@CR35]\], such as live virus, killed virus, and conjugate vaccines, have failed to produce a promising vaccine against several clinically important viruses, including HIV/AIDS \[[@CR36]\]. Therefore, short peptide vaccines are promising solutions for viral vaccine development. It should be noted that there are many other viruses for which vaccines are needed. Examples of additional viruses for which there are no vaccines available, vaccines are still under development, vaccine failures occurred, or more effective vaccines are needed include RSV, measles, HBV, WNV, Coronaviruses, H5N1 influenza virus, HCV, Adenovirus, Hantavirus, and Filoviruses \[[@CR37]--[@CR47]\].

Conclusion {#Sec10}
==========

The design and development of short peptide cocktail vaccines is a possibility in the near future. This function on the principle of short epitopes developed through the binding of CD8+/CD4+-specific HLA alleles. HLA molecules are specific within ethnic populations and are polymorphic with more than 12542 known alleles as of March 2015. Thus, the binding of short peptide antigens to HLA alleles is rate limiting yet specific, with high sensitivity, while producing T-cell-mediated immune responses. Our understanding of this specific peptide binding to HLA alleles has improved using known HLA-peptide complexes. There is a search for superantigen peptides covering major HLA supertypes. Thus, peptide-binding predictions with large coverage, accuracy, sensitivity, and specificity are essential for vaccine candidate design and development. It should be noted that available HLA-peptide binding prediction methods are highly promising in these directions.
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